

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH			2a. AGE <b>23</b> Years	3. SEX <b>Female</b>	3a. WEIGHT <b>85.40</b> kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY  <input type="checkbox"/> OTHER
		Day	Month	Year			Day	Month	Year		
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) <b>episodes of diarrhea [Diarrhoea]</b> <b>a lot of stress [Stress]</b> <b>Saxenda used in 5 clicks [Wrong technique in product usage process]</b> <b>Dosage of Saxenda 1.2 +5 clicks : Incorrect dose administered [Incorrect dose administered]</b>  Case Description: ***This is an auto generated narrative***  Study ID: 828652-My Healthy Journey											

(Continued on Additional Information Page)

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) <b>#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL</b>		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) <b>#1 ) 1.8 mg, qd</b>		16. ROUTE(S) OF ADMINISTRATION <b>#1 ) Subcutaneous</b>
17. INDICATION(S) FOR USE <b>#1 ) Obesity (Obesity)</b>		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) <b>#1 ) JAN-2025 / Unknown</b>		19. THERAPY DURATION <b>#1 ) Unknown</b>

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) <b>#1 ) BELARA (CHLORMADINONE ACETATE, ETHINYLESTRADIOL) ; Unknown</b>		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates <b>Unknown to Ongoing</b>	Type of History / Notes <b>Current Condition</b>	Description <b>Obesity (Obesity)</b>
<b>Unknown</b>	<b>Duration not reported</b>	<b>Contraception (Contraception)</b>

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER <b>Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888</b>		26. REMARKS <b>Medically Confirmed: No</b>
24b. MFR CONTROL NO. <b>1423070</b>		25b. NAME AND ADDRESS OF REPORTER <b>NAME AND ADDRESS WITHHELD.</b>
24c. DATE RECEIVED BY MANUFACTURER <b>28-APR-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT <b>23-JUN-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 158 cm.

Patient's weight: 85.4 kg.

Patient's BMI: 34.20926130.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "episodes of diarrhea(Diarrhea)" beginning on APR-2025 , "a lot of stress(Stress)" beginning on APR-2025 , "Saxenda used in 5 clicks(Wrong technique in product usage process)" beginning on JAN-2025 , "Dosage of Saxenda 1.2 +5 clicks : Incorrect dose administered(Incorrect dose administered)" beginning on JAN-2025 and concerned a 23 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from JAN-2025 and ongoing for "Obesity",

Dosage Regimens:

Saxenda: ??-JAN-2025 to Not Reported, Not Reported to Not Reported (Dosage Regimen Ongoing);

Current Condition: Obesity

Procedure: Contraceptives.

Concomitant medications included - BELARA(CHLORMADINONE ACETATE, ETHINYLESTRADIOL).

Treatment medications included - ENTEROGERMINA [BACILLUS CLAUSII](BACILLUS CLAUSII).

Batch Numbers:

Saxenda: UNK, UNK;

Action taken to Saxenda was reported as Dose Decreased.

On APR-2025 the outcome for the event "episodes of diarrhea(Diarrhea)" was Recovered.

On APR-2025 the outcome for the event "a lot of stress(Stress)" was Recovered.

The outcome for the event "Saxenda used in 5 clicks(Wrong technique in product usage process)" was Not recovered.

The outcome for the event "Dosage of Saxenda 1.2 +5 clicks : Incorrect dose administered(Incorrect dose administered)" was Not recovered.

Reporter's causality (Saxenda) -

episodes of diarrhea(Diarrhea) : Unknown

a lot of stress(Stress) : Unknown

Saxenda used in 5 clicks(Wrong technique in product usage process) : Unknown

Dosage of Saxenda 1.2 +5 clicks : Incorrect dose administered(Incorrect dose administered) : Unknown

Company's causality (Saxenda) -

episodes of diarrhea(Diarrhea) : Possible

a lot of stress(Stress) : Unlikely

Saxenda used in 5 clicks(Wrong technique in product usage process) : Possible

Dosage of Saxenda 1.2 +5 clicks : Incorrect dose administered(Incorrect dose administered) : Possible

**14-19. SUSPECT DRUG(S) continued**

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL; Regimen #2	New dosage: 1.2 + 5 clicks; Subcutaneous	Obesity (Obesity)	Ongoing; Unknown